Off-the-shelf consumer wearables have shown a benefit when used to monitor the response to treatment in patients with atrial fibrillation (AF) and heart failure (HF).
AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower
New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss.
The FDA has cleared an artificial intelligence algorithm that can detect signs of heart failure in seconds using a digital stethoscope during a standard physical exam.
An intriguing new study has suggested that there could be a correlation between the built environment of an area – its buildings, streets, and green spaces – and the risk
MSD’s sotatercept has become the first FDA-approved therapy for pulmonary arterial hypertension (PAH) that addresses the underlying mechanism behind the disease, rather th
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company